PRI's Focus on Health Care

View this email in your browser ([link removed])
[link removed]
Giving The Gov't Drug Patent March-In Authority Is Bad Policy
Law360 | Wayne Winegarden | December 13, 2023

In early December, the Biden administration announced a proposal on exercising march-in rights on taxpayer-funded drugs and other inventions that allows prices to “be a factor in considering whether a drug is accessible to the public.” This is a terrible idea.

As the Congressional Research Service summarized, it is an unsettled question whether high prices can be used to justify the government’s use of march-in authority — a question that may ultimately be litigated should the rule be finalized. Unlike the legal issue, there is no question regarding the adverse economic and health consequences of this proposed rule.

Read here . . . ([link removed])
GOP Shouldn't Squander Trump's Revival of Obamacare Debate
Newsmax | Sally C. Pipes | December 13, 2023

Former President Donald Trump recently revealed he is “seriously looking at alternatives” to Obamacare.

As he put it in a post on Truth Social ([link removed]) , “[t]he cost of Obamacare is out of control, plus, it’s not good Healthcare.”

Those comments should have come as good news to lawmakers looking to reduce the role of government in healthcare.

Read more... ([link removed])

[link removed]

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Website ([link removed])
Copyright © 2022 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116

** ([link removed])

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.